Global Focal Segmental Glomerulosclerosis Drugs Market Forecast to Reach $24.79 Billion by 2029, Driven by 9.9% CAGR
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Focal Segmental Glomerulosclerosis Drugs Market Heading Into 2029?
The market size for focal segmental glomerulosclerosis medication has seen robust growth in the past few years. The prediction is that the market will expand from $15.77 billion in 2024 to $17 billion in 2025, at a compound annual growth rate (CAGR) of 7.8%. The expansion witnessed throughout the historical period can be credited to factors like a rise in disease prevalence, mounting demand for innovative treatments, escalating interest among the pharmaceutical sector, and augmented government backing.
Expectations suggest that the market for focal segmental glomerulosclerosis drugs will experience robust growth in the coming years. The market is projected to reach an impressive “$24.79 billion by 2029 with a 9.9% compound annual growth rate (CAGR).” Factors contributing to this growth for the projected period include research and development spending, heightened healthcare expenditure, increased knowledge and diagnosis, elderly population, and governmental support and funding. There are key future trends to note, such as technological progress in drug research and creation, growth in clinical trial pipelines, better reimbursement policies for focal segmental glomerulosclerosis drug therapies, and corporate research facility expansion.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12866&type=smp
Which Factors Are Pushing The Focal Segmental Glomerulosclerosis Drugs Market Forward?
The increasing occurrence of kidney infections is projected to boost the growth of the focal segmental glomerulosclerosis (FSGS) drugs market in the future. Pyelonephritis, a serious urinary tract infection, can impact one or both kidneys. FSGS drugs, employed in the treatment of kidney diseases, bring numerous advantages in handling the situation and enhancing kidney function by reducing proteinuria, delaying kidney damage progression, and providing improved quality of life for those suffering from kidney diseases. For example, the Centers for Disease Control and Prevention, an agency within the Department of Health and Human Services in the United States, reported in July 2022 that approximately 15% or 37 million individuals in the United States were affected by kidney disease. The incidence rate for those aged between 45 and 64 was 12%, whereas it was 6% for those between 18 and 44 in 2021. Consequently, the increasing occurrence of kidney infections is driving the FSGS market’s growth.
The focal segmental glomerulosclerosis drugs market covered in this report is segmented –
1) By Type: Losmapimod, SHP-627, Sparsentan, TM-5484, Other Types
2) By Treatment: Corticosteroids, Immunosuppressive Drugs, Angiotensin Converting Enzymes (ACE) Inhibitors, A.R. Blockers, Diuretics, Other Treatments
3) By Route of Administration: Oral, Parenteral
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
What Are The Leading Trends And Opportunities In The Focal Segmental Glomerulosclerosis Drugs Sector?
Leading enterprises in the focal segmental glomerulosclerosis (FSGS) market are placing a greater emphasis on product innovation and development, to deliver dependable products to consumers and solidify their market dominance. Take for example, the U.S. biopharmaceutical firm named Travere Therapeutics, that in February 2023 introduced FILSPARI, a product for treating FSGS, approved by the Food and Drug Administration (FDA), a federal agency in the US. This orally administered drug is for treating IgA nephropathy (IgAN), and it is the first solitary non-immunosuppressive treatment to reduce proteinuria in IgAN, an uncommon kidney-related illness. Additionally, both in Europe and the United States, FILSPARI has been bestowed with the orphan drug designation for the treatment of IgAN and focal segmental glomerulosclerosis (FSGS).
Which Organizations Are Driving Progress In The Focal Segmental Glomerulosclerosis Drugs Industry?
Major companies operating in the focal segmental glomerulosclerosis drugs market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Fresenius Kabi Ltd., GSK PLC, Medtronic Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Alexion Pharmaceuticals, Wockhardt, Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio.
Which Region Is Expected To Experience The Highest Growth In The Focal Segmental Glomerulosclerosis Drugs Industry?
North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2024. The regions covered in the focal segmental glomerulosclerosis (FSGS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12866&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
